Practice Direction
Sale of NAPRA Schedule 3 Drugs
(non-prescription, pharmacy only sales)

1.0 Scope and Objective:

1.1 Expected Outcome

This document is a practice direction of Council concerning the sale of NAPRA “Schedule 3 of the Manual” Drugs through the authority of The Pharmaceutical Regulations to The Pharmaceutical Act and The Pharmaceutical Act.

1.2 Document Jurisdiction (Area of Practice)

Schedule 3 drugs must only be distributed from a licensed community pharmacy as described under section 84(4) of the regulations.

1.3 Regulatory Authority Reference

Schedule 3 drugs may be sold in a self-selection area of the pharmacy under the direct supervision of a licensed pharmacist who is available to assist the patient or designate in medication selection.

2.0 Practice Direction

2.1 A licensed pharmacist must be available and accessible in-person to an individual who needs to make self-selection of a Schedule 3 drug to provide an opportunity for an assessment or to assist with the individual’s self-selection.

2.2 Schedule 3 drugs shall only be sold in a licensed community pharmacy; and,

2.3 The sale of Schedule 3 drugs are not permitted for online sale, as the pharmacist does not have the opportunity to conduct an in-person assessment, or assist with the patient’s self-selection.
2.4 A licensed pharmacist should take the necessary steps to enter into dialogue with, or provide information to, the patient or the designate who:
   a) requests help in selecting a Schedule 3 drug;
   b) appears to be having difficulty in selecting a Schedule 3 drug;
   c) is observed to be making frequent or repeat purchases of a Schedule 3 drug or purchasing a quantity that is therapeutically inappropriate; or
   d) is recognized as someone who presents a risk from the use of a Schedule 3 drug.

2.5 When engaging in a dialogue, the licensed pharmacist should gather specific information such as:
   2.5.1 the condition or symptom(s) to be treated;
   2.5.2 any previous history of complaint given as well as length of present symptoms;
   2.5.3 current and relevant information regarding disease state(s), allergies and/or sensitivities;
   2.5.4 current medications; and/or
   2.5.5 other medications or therapies previously tried.

2.6 Dialogue must occur in a confidential manner.

2.7 The licensed pharmacist will enable the patient to make a choice and will discuss:
   2.7.1 if recommending a drug therapy, directions for proper use and length of therapy, common adverse effects, and expected response or outcome or benefit(s);
   2.7.2 non-drug treatments, if any;
   2.7.3 follow-up with the licensed pharmacist or another health care professional if there is no improvement or symptoms change or worsen;
   2.7.4 the need for referral to another health care professional if the condition or symptom(s) are deemed to be serious in nature; if unsure of the diagnosis or if the situation cannot be appropriately treated with non-prescription drugs; and,
   2.7.5 the need for further dialogue with the patient directly (if a designate is involved or if a drug product is being delivered).

2.8 A licensed pharmacist will document the patient interaction and any recommendation(s) in the patient’s health record, if such documentation is deemed appropriate.
2.9 A licensed pharmacist may refuse the sale of a Schedule 3 Drug.

3.0 Compliance Adjudication

All documentation must be readily accessible and open to regulatory review.

4.0 Appendices

Not applicable